BNIGF (Beroni Group) ROC (Joel Greenblatt) %: -60.93% (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNIGF Beroni Group Ltd BNIGF
4 GF Score
Price $0.01
View Full Analysis

What is Beroni Group ROC (Joel Greenblatt) %?

Beroni Group BNIGF 4 ROC (Joel Greenblatt) % is -60.93% as of Jun. 2024. GuruFocus rates BNIGF with a GF Score™ of 4/100.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Beroni Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -60.93%.

The historical rank and industry rank for Beroni Group's ROC (Joel Greenblatt) % or its related term are showing as below:

BNIGF's ROC (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 11.405
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Beroni Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Beroni Group  (OTCPK:BNIGF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Beroni Group ROC (Joel Greenblatt) % Related Terms


Beroni Group ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Beroni Group's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beroni Group ROC (Joel Greenblatt) % Chart

Beroni Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -109.59 -259.05 -181.68 -344.60 -449.23

Beroni Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -312.68 -329.08 -309.47 -767.43 -60.93

BNIGF vs PNXP, CRYM, GCAN: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beroni Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beroni Group ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beroni Group's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Beroni Group's ROC (Joel Greenblatt) % falls into.


BNIGF
4GF Score
Beroni Group Ltd BNIGF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beroni Group ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.219 + 0.07 + 0.587) - (0.257 + 0 + 3.229)
=-2.61

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.218 + 0.076 + 0.589) - (0.685 + 0 + 0.273)
=-0.075

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Beroni Group for the quarter that ended in Jun. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.492/( ( (0.845 + max(-2.61, 0)) + (0.77 + max(-0.075, 0)) )/ 2 )
=-0.492/( ( 0.845 + 0.77 )/ 2 )
=-0.492/0.8075
=-60.93 %

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -60.93% mean?
Beroni Group (BNIGF) has a ROC (Joel Greenblatt) % of -60.93% as of Jun. 2024. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Beroni Group and its competitors.
Is Beroni Group's ROC (Joel Greenblatt) % too high?
Beroni Group's current ROC (Joel Greenblatt) % is -60.93%. Overall, Beroni Group has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's ROC (Joel Greenblatt) % compare to PNXP and CRYM?
Beroni Group's ROC (Joel Greenblatt) % of -60.93% can be compared against companies in the Drug Manufacturers industry. The industry median ROC (Joel Greenblatt) % is 11.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Beroni Group and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beroni Group's current ROC (Joel Greenblatt) % is -60.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (BNIGF) has a current ROC (Joel Greenblatt) % of -60.93%. The current ROC (Joel Greenblatt) % is -60.93%. Beroni Group's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Beroni Group (BNIGF), the current ROC (Joel Greenblatt) % is -60.93% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beroni Group Business Description

Address 175 Pitt Street, Level 16, Sydney, NSW, AUS, 2000
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
4GF Score

Get the complete analysis for BNIGF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price